Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[EM]

TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research

Treatment with TyrNovo's NT219 in combination with targeted cancer drugs, as well as chemotherapy and immuno-oncology therapies, prevented acquired resistance and reversed resistance of colon, lung and head-and-neck cancers in patient-derived xenograft models.

TEL AVIV, Israel, April 13, 2018 /PRNewswire/ -- Kitov Pharma (NASDAQ and TASE: KTOV), today announced that TyrNovo Ltd., a company majority-owned by Kitov, will present pre-clinical data on TyrNovo's anti-tumor resistance drug candidate, NT219, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2018, to be held on April 14-18, at the McCormick Place, Chicago, Illinois.

The poster highlights recent promising results, further demonstrating NT219's efficacy in synergy with immuno-oncology therapies. The recent results, achieved using double autologous PDX models, demonstrated that NT219 converted non-responding tumors to responders to pembrolizumab (Keytruda®). The models also demonstrated the efficacy of NT219 in enhancing the immunotherapeutic potential of cetuximab (Erbitux®).

Details on the poster presentations are as follows:

Session Title: Immune Mechanisms Invoked by Therapies 1

Session Time: 4/16/2018 1:00 PM - 5:00 PM ET
Location: Poster Section 33
Poster Board Number: 2754 / 16

http://kitovpharma.investorroom.com/2018-04-13-TyrNovo-to-Present-at-2018-Annual-Meeting-of-the-American-Association-for-Cancer-Research